NICE recommendation of darolutamide plus hormone therapy for metastatic prostate cancer offers around 6000 patients in ...

Prostate cancer screening for men over 70 is complex, with current recommendations against routine PSA testing due to slow ...

Targeting prostate-specific membrane antigen, Lu-PSMA-617 has demonstrated clinical benefits in patients with PSMA-positive ...

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...

A Biden spokeswoman confirmed the former president finished several weeks of radiation therapy treatment Monday.

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

Men with incurable prostate cancer are facing a “postcode lottery of care” a charity has warned after it raised concerns that ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...